NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE CAP
Vir Biotechnology, Inc. VIR
9 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$68.6M
▼ 7.6% vs FY2024
EPS · FY25
$-3.16
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
-638.9%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 68.6M
Revenue, FY2025 · full 9-year series below
Revenue
Net income
The company lost 639 cents on every revenue dollar this year.
Per share
USD -3.16
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin-699.2%
Net margin-638.9%
Return on assets-36.5%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−2.1% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−65.1%
−2.1%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.14B
Shares outstanding, FY2025
Change, 5 years+9.5%
Change, 10 years—
The share count grew 9% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 1.0B
total assets, end of FY2025
Total assetsUSD 1.0B
CashUSD 232.2M
Current ratio5.54×
History
9 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue $B
0.1
0.1
0.1
1.6
1.1
0.1
0.0
0.0
0.0
Operating income $B
−0.5
−0.6
−0.7
0.8
0.4
−0.3
−0.2
−0.1
−0.1
EBITDA $B
−0.5
−0.6
−0.7
0.8
0.4
−0.3
−0.2
−0.1
−0.1
Income tax $B
0.0
−0.0
−0.0
0.2
0.0
0.0
0.0
−0.0
−0.0
Net income $B
−0.4
−0.5
−0.6
0.5
0.5
−0.3
−0.2
−0.1
−0.1
EPS, diluted $
−3.16
−3.83
−4.59
3.83
3.96
−2.51
−5.76
−15.12
−32.45
Dividend / sh $
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
ROE %
·
·
−29.6
29.4
49.2
−52.4
−142.7
·
·
Shares out B
0.14
0.14
0.13
0.13
0.13
0.13
0.11
0.01
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
25 of 25
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed